ACE2 and chronic obstructive pulmonary disease: ICS therapies in COPD reduce expression of the ACE2 (Angiotensin Converting Enzyme 2) receptor, which is highly expressed in the upper respiratory tract of humans as the point of entry for SARS-CoV-2 [14, 15].